ALTAltimmune, Inc.

$353M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000-98.6% YoY

Gross Profit

$5,000100.0% margin

Operating Income

-$25M-495340.0% margin

Net Income

-$23M-456900.0% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$148M

Total Liabilities

$14M

Stockholders' Equity

$133M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$362,000	-98.6%
Gross Profit	$5,000	-$18M	+100.0%
Operating Income	-$25M	-$23M	-9.9%
Net Income	-$23M	-$21M	-10.5%

ALT Q3 2024 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena